Showing results (201-210 of 262) with videos related to

Sort By:
Pageof 27
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2026
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysisSophie Wollnitza, David Ventura, Marcel Teichert, et al.
The EMBO Journal|August 31, 2016
Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitorsPia Riemke, Melinda Czeh, Josephine Fischer, et al.
Cancers|August 12, 2022
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective AnalysisEvgenii Shumilov, Lena Aperdannier, Nicole Schmidt, et al.
Blood|April 28, 2010
Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profilingElena M Hartmann, Elias Campo, George Wright, et al.
Blood Advances|April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapseAndrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Oncogene|February 27, 2022
Targeted siRNA nanocarrier: a platform technology for cancer treatmentNicole Bäumer, Jessica Tiemann, Annika Scheller, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
American Journal of Hematology|December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 studyMartin Dreyling, Armando Santoro, Luigina Mollica, et al.
The Journal of Experimental Medicine|March 14, 2007
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphomaGeorg Lenz, Inga Nagel, Reiner Siebert, et al.
Leukemia|June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapyMaxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
Pageof 27